Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04975399 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT04975399 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 26 participants.
The verdict
NCT04975399, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This Phase 1, first-in-human (FIH), clinical study of CC-92328 will explore the safety, tolerability and preliminary biological and clinical activity of CC-92328 as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM). The study will be conducted in two parts: monotherapy dose escalation (Part A) and monotherapy dose expansion (Part B).
Interventions
- DRUG CC-92328
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2021-10-05 |
| Est. Completion | 2024-06-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04975399
The ClinicalTrials.gov registry entry for NCT04975399 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CC-92328 is the first listed.
NCT04975399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04975399 about?
NCT04975399 is a clinical study titled "Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma". This Phase 1, first-in-human (FIH), clinical study of CC-92328 will explore the safety, tolerability and preliminary biological and clinical activity of CC-92328 as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM). The study will be conducted in two parts: monoth...
What is the current status of trial NCT04975399?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2021-10-05. Estimated completion is 2024-06-18.
What interventions are being tested in trial NCT04975399?
The interventions under investigation include: CC-92328 (DRUG).
Who is sponsoring clinical trial NCT04975399?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.